Skip to main content
Clinical Trials/IRCT20080901001165N61
IRCT20080901001165N61
Not yet recruiting
Phase 3

Investigating the comparative preventive efficacy and safety of FluGaurd® (a 4-valent recombinant influenza vaccine, produced by Niwad-Pharmed-Salamat company, I.R.Iran), to Vaxigrip® (produced by Sanofi company, France) as the reference product in Healthy volunteers

iwad-Pharmed-Salamat company0 sites200 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
iwad-Pharmed-Salamat company
Enrollment
200
Status
Not yet recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
iwad-Pharmed-Salamat company

Eligibility Criteria

Inclusion Criteria

  • The age of the volunteer is between 18 and 49 years.
  • The volunteer has general health (through clinical examinations and medical records).
  • The volunteer or his/her legal guardian must have signed the informed consent form.
  • The volunteer must be able to keep up with the monitoring programs.

Exclusion Criteria

  • Have a history of previous vaccinations against influenza strains used in injectable vaccines;
  • Have a history of allergy to Vaxigrip;
  • History of chronic use (more than 14 days) immunosuppressive drugs in the last 6 months (in the case of corticosteroids, prednisolone (or its equivalents) in the amount of 0\.5 mg per kg of volunteer weight per day. Topical or inhaled steroids usage are free.)
  • History of any immune system disorders such as Guillain\-Barré syndrome and other Masculoscletal disorders;
  • History of chronic diseases such as cancer, liver and kidney disease, neurological disorders, diabetes;
  • History of receiving immunoglobulins or other blood products 90 days before the vaccine injection;

Outcomes

Primary Outcomes

Not specified

Similar Trials